China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A

China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A

SSSE:600750
23.57
CNY
+0.25
(+1.07%)
1.48EPS
16.85P/E
14.32BMarket Cap
Mar 19Next Earn

Total Valuation

CNY

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A carries a market capitalization of 14.32B, placing it among publicly traded companies globally. Its enterprise value stands at 14.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap14.32B
Enterprise Value14.36B

Important Dates

China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for March 19, 2027.

Earnings Date3/19/2027

Share Statistics

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A has 635.59M shares outstanding.

Shares Outstanding635.59M

Valuation Ratios

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 16.85. The price-to-sales ratio is 3.59, and the price-to-book ratio stands at 3.80.

PE Ratio16.85
PS Ratio3.59
PB Ratio3.80
P/TBV Ratio4.35

Enterprise Valuation

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 13.49 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.64 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.36B versus a market cap of 14.32B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.64
EV / EBITDA13.49
EV / EBIT13.49

Financial Position

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.22, indicating conservative leverage, while an interest coverage ratio of 453.58 demonstrates strong ability to service its debt obligations.

Current Ratio1.46
Quick Ratio0.38
Debt / Equity0.22
Debt / EBITDA0.01
Interest Coverage453.58

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 907,224.24 in revenue per employee across its workforce of 4,352.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee907,224.24
Employee Count4,352.00

Taxes

CNY

Over the twelve months ended September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A recorded 168.34M in income tax expense. That works out to an effective tax rate of 15.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.10B, leaving 840.55M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax168.34M
Effective Tax Rate15.28

Stock Price Statistics

CNY

As of the close on November 17, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A's stock has gained approximately 7.53% over the past 52 weeks. The 50-day moving average sits at 22.81, while the 200-day moving average is 24.30.

52-Week Price Change7.53%
50-Day Moving Average22.81
200-Day Moving Average24.30

Income Statement

CNY

Over the twelve months ended September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A generated 3.95B in revenue and converted that into 840.55M in net income, yielding earnings per share of 1.48. EBITDA reached 1.06B, while operating income came in at 1.01B.

Revenue3.95B
Gross Profit2.57B
Operating Income1.01B
Pretax Income1.10B
Net Income840.55M
EBITDA1.06B
EBIT1.06B
Earnings Per Share (EPS)1.48

Balance Sheet

CNY

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A holds 705.81M in cash and equivalents against 10.05M in total debt, resulting in a net debt position of -275.48M. Total book value stands at 3.77B, with working capital of 856.92M providing operational flexibility.

Cash & Cash Equivalents705.81M
Total Debt10.05M
Net Debt-275.48M
Equity (Book Value)3.77B
Book Value Per Share5.93
Working Capital856.92M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-228.67M

Margins

Over the twelve months ended September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A posted a gross margin of 65.10, reflecting its pricing power and cost economics. The operating margin of 25.47 and net profit margin of 21.29 provide insight into operational efficiency.

Gross Margin65.10
Operating Margin25.47
Pretax Margin27.90
Profit Margin21.29
EBITDA Margin26.96

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A paid dividends of 1.04 per share. The dividend payout ratio of 63.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 6.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A shareholders.

Dividend Per Share1.04
Payout Ratio63.59
Shareholder Yield6.77

Stock Splits

China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 12, 2020 with a 5:6 split ratio.

Last Split Date6/12/2020
Split Ratio5:6

Scores

As of September 30, 2026, China Resources Jiangzhong Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 5.93, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.93